0
Upcoming Allied Market Research
2023
Asia Pacific Hormone Refractory Breast Cancer Market

Asia Pacific Hormone Refractory Breast Cancer Market

by TREATMENT (Tumor Markers Therapy, Gene Expression Therapy, Gene Mutation Therapy, Others), by Application (Scientific Research and Production, Medical Technology, Biological Science and Technology, Others): Global Report opportunity Analysis and Industry Forecast, 2022-2032

Report Code: A01037
Nov 2023 | Pages: NA
Tables: NA
Charts: NA
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Asia Pacific Hormone Refractory Breast Cancer Market

Request Now !

Breast cancer is the most common type of malignant cancer prevalent in women above the age of 40. According to the estimates of World Health Organization, cancer is the most fatal human disease accounting for the deaths of ~8.2 million people worldwide in 2012. Among these deaths, breast cancer was found to be most prominent disease among women that killed ~521,000 individuals. Presently, increasing number of hormone therapies have made refractory breast cancers resistant toward therapeutics, termed as hormone-resistant breast cancers. However, recently developed hormone refractory breast cancer chemotherapeutic agents such as, trastuzumab and everolimus, alone or in combination, are under clinical trials for the effective treatment of hormone refractory breast cancers.

Key factors responsible for the growth of this market involve increasing incidences of breast cancers, aging population, demands of advanced therapeutics, increasing prevalence of hormone refractory breast cancers, and the presence of a significant number of anticancer pipeline drugs. Rising life span of cancer-affected population is one of the other factors responsible for the growth of this market. However, social stigma of testing breast cancer lacks technological reach. Insufficient advanced chemotherapeutic treatments restraining the hormone refractory breast cancer market. Substantial number of new chemical entities (NCEs) in various phases of clinical trials will emerge as potential opportunities in the Asia Pacific market.

The Asia Pacific hormone refractory breast cancer market is segmented into China, Japan, India, Australia and others. The Asia-Pacific region is expected to rise at the significant pace, owing to rapid growth of pharmaceutical and healthcare industry along with the improved purchasing power of the service providers in this region. Rapidly emerging economies and the rise of medical tourism in regions such as India and China, will drive the growth of hormone refractory breast cancer market. Rising kidney failure, prevalence rates, in the Asia-Pacific regions should boost the growth of this market.

KEY BENEFITS

  • The analysis, made in this report, helps in understanding the strategies adopted by various companies for gaining market share in hormone refractory breast cancer market
  • This report provides a comprehensive analysis of factors that drive and restrict the growth of the hormone refractory breast cancer market
  • Detailed study of the strategies of key leaders, partnerships, and acquisitions in the Asia Pacific hormone refractory breast cancer market would be informative for professionals in the corporate sector
  • Pin-point analysis of geographic segments helps to identify opportunities for growth within the hormone refractory breast cancer market
  • An analysis for the market attractiveness has been included for therapeutics, devices, and geographic regions along with a detailed analysis of factors responsible for the rapid growth of the market segments
  • Ease of doing business analysis should help in making strategic business decisions

ASIA-PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET KEY SEGMENTS

BY TREATMENT MODALITY

  • Hormone receptor-based therapy
  • Tumor markers therapy
  • Gene expression therapy
  • Gene mutation therapy

BY GEOGRAPHY

  • China
  • Japan
  • India
  • Australia
  • Others

Asia Pacific Hormone Refractory Breast Cancer Market Report Highlights

Aspects Details
By TREATMENT
  • Tumor Markers Therapy
  • Gene Expression Therapy
  • Gene Mutation Therapy
  • Others
By Application
  • Scientific Research and Production
  • Medical Technology
  • Biological Science and Technology
  • Others
By Region
  • North America  (UNITED STATES, CANADA, MEXICO)
  • Europe  (FRANCE, GERMANY, ITALY, SPAIN, UNITED KINGDOM, Rest of Europe)
  • Asia-Pacific  (CHINA, JAPAN, INDIA, SOUTH KOREA, AUSTRALIA, Rest of Asia Pacific)
  • LAMEA  (Brazil, South Africa,, Saudi Arabia, Rest of LAMEA)
Key Market Players NeoCorp GmbH, Boehringer Ingelheim GmbH, AstraZeneca, Bluefish Pharmaceuticals AB, AmpliMed Corporation, F. Hoffmann La Roche, Fresenius Kabi, Sanofi Genzyme, Neopharm, Anant Pharmaceuticals Pvt. Ltd.
 

TABLE OF CONTENTS

  • CHAPTER 1:    INTRODUCTION

    • 1.1.   Report description

    • 1.2.   Key benefits for stakeholders

    • 1.3.   Key market segments

    • 1.4.   Research methodology

      • 1.4.1.   Secondary research

      • 1.4.2.   Primary research

    • 1.5.   Analyst tools and models

    CHAPTER 2:    EXECUTIVE SUMMARY

    • 2.1.   Key findings of the study

    • 2.2.   CXO perspective

    CHAPTER 3:    MARKET OVERVIEW

    • 3.1.   Market definition and scope

    • 3.2.   Key findings

      • 3.2.1.   Top investment pockets

    • 3.3.   Porter’s five forces analysis

    • 3.4.   Market dynamics

      • 3.4.1.   Drivers

      • 3.4.2.   Restraint

      • 3.4.3.   Opportunity

    • 3.6.   COVID-19 Impact Analysis

  • CHAPTER 4 : ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET, TREATMENT

    • 4.1.   Overview

      • 4.1.1 Market size and forecast, treatment

    • 4.2.   Tumor Markers Therapy

      • 4.2.1. Key market trends, growth factors and opportunities

      • 4.2.2. Market size and forecast

      • 4.2.3. Market share analysis, by country

    • 4.3.   Gene Expression Therapy

      • 4.3.1. Key market trends, growth factors and opportunities

      • 4.3.2. Market size and forecast

      • 4.3.3. Market share analysis, by country

    • 4.4.   Gene Mutation Therapy

      • 4.4.1. Key market trends, growth factors and opportunities

      • 4.4.2. Market size and forecast

      • 4.4.3. Market share analysis, by country

    • 4.5.   Others

      • 4.5.1. Key market trends, growth factors and opportunities

      • 4.5.2. Market size and forecast

      • 4.5.3. Market share analysis, by country

  • CHAPTER 5 : ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET, APPLICATION

    • 5.1.   Overview

      • 5.1.1 Market size and forecast, application

    • 5.2.   Scientific Research and Production

      • 5.2.1. Key market trends, growth factors and opportunities

      • 5.2.2. Market size and forecast

      • 5.2.3. Market share analysis, by country

    • 5.3.   Medical Technology

      • 5.3.1. Key market trends, growth factors and opportunities

      • 5.3.2. Market size and forecast

      • 5.3.3. Market share analysis, by country

    • 5.4.   Biological Science and Technology

      • 5.4.1. Key market trends, growth factors and opportunities

      • 5.4.2. Market size and forecast

      • 5.4.3. Market share analysis, by country

    • 5.5.   Others

      • 5.5.1. Key market trends, growth factors and opportunities

      • 5.5.2. Market size and forecast

      • 5.5.3. Market share analysis, by country

  • CHAPTER 6 : ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET, BY REGIONS

    • 6.1.  Overview

    • 6.2.  NORTH AMERICA

      • 6.2.1. Key market trends, growth factors, and opportunities

      • 6.2.2. Market size and forecast, treatment

      • 6.2.3. Market size and forecast, application

      • 6.2.4. Market size and forecast, by region

      • 6.2.5. Market size and forecast, by country

      • 6.2.6. UNITED STATES

        • 6.2.6.1 Market size and forecast, treatment

        • 6.2.6.2 Market size and forecast, application

      • 6.2.7. CANADA

        • 6.2.7.1 Market size and forecast, treatment

        • 6.2.7.2 Market size and forecast, application

      • 6.2.8. MEXICO

        • 6.2.8.1 Market size and forecast, treatment

        • 6.2.8.2 Market size and forecast, application

    • 6.3.  EUROPE

      • 6.3.1. Key market trends, growth factors, and opportunities

      • 6.3.2. Market size and forecast, treatment

      • 6.3.3. Market size and forecast, application

      • 6.3.4. Market size and forecast, by region

      • 6.3.5. Market size and forecast, by country

      • 6.3.6. FRANCE

        • 6.3.6.1 Market size and forecast, treatment

        • 6.3.6.2 Market size and forecast, application

      • 6.3.7. GERMANY

        • 6.3.7.1 Market size and forecast, treatment

        • 6.3.7.2 Market size and forecast, application

      • 6.3.8. ITALY

        • 6.3.8.1 Market size and forecast, treatment

        • 6.3.8.2 Market size and forecast, application

      • 6.3.9. SPAIN

        • 6.3.9.1 Market size and forecast, treatment

        • 6.3.9.2 Market size and forecast, application

      • 6.3.10. UNITED KINGDOM

        • 6.3.10.1 Market size and forecast, treatment

        • 6.3.10.2 Market size and forecast, application

      • 6.3.11. Rest of Europe

        • 6.3.11.1 Market size and forecast, treatment

        • 6.3.11.2 Market size and forecast, application

    • 6.4.  ASIA-PACIFIC

      • 6.4.1. Key market trends, growth factors, and opportunities

      • 6.4.2. Market size and forecast, treatment

      • 6.4.3. Market size and forecast, application

      • 6.4.4. Market size and forecast, by region

      • 6.4.5. Market size and forecast, by country

      • 6.4.6. CHINA

        • 6.4.6.1 Market size and forecast, treatment

        • 6.4.6.2 Market size and forecast, application

      • 6.4.7. JAPAN

        • 6.4.7.1 Market size and forecast, treatment

        • 6.4.7.2 Market size and forecast, application

      • 6.4.8. INDIA

        • 6.4.8.1 Market size and forecast, treatment

        • 6.4.8.2 Market size and forecast, application

      • 6.4.9. SOUTH KOREA

        • 6.4.9.1 Market size and forecast, treatment

        • 6.4.9.2 Market size and forecast, application

      • 6.4.10. AUSTRALIA

        • 6.4.10.1 Market size and forecast, treatment

        • 6.4.10.2 Market size and forecast, application

      • 6.4.11. Rest of Asia Pacific

        • 6.4.11.1 Market size and forecast, treatment

        • 6.4.11.2 Market size and forecast, application

    • 6.5.  LAMEA

      • 6.5.1. Key market trends, growth factors, and opportunities

      • 6.5.2. Market size and forecast, treatment

      • 6.5.3. Market size and forecast, application

      • 6.5.4. Market size and forecast, by region

      • 6.5.5. Market size and forecast, by country

      • 6.5.6. Brazil

        • 6.5.6.1 Market size and forecast, treatment

        • 6.5.6.2 Market size and forecast, application

      • 6.5.7. South Africa,

        • 6.5.7.1 Market size and forecast, treatment

        • 6.5.7.2 Market size and forecast, application

      • 6.5.8. Saudi Arabia

        • 6.5.8.1 Market size and forecast, treatment

        • 6.5.8.2 Market size and forecast, application

      • 6.5.9. Rest of LAMEA

        • 6.5.9.1 Market size and forecast, treatment

        • 6.5.9.2 Market size and forecast, application

  • CHAPTER 7 : COMPANY PROFILES

    • 7.1. ASTRAZENECA

      • 7.1.1. Company overview

      • 7.1.2. Business performance

      • 7.1.3. Key strategic moves and developments

    • 7.2. AMPLIMED CORPORATION

      • 7.2.1. Company overview

      • 7.2.2. Business performance

      • 7.2.3. Key strategic moves and developments

    • 7.3. F. HOFFMANN LA ROCHE

      • 7.3.1. Company overview

      • 7.3.2. Business performance

      • 7.3.3. Key strategic moves and developments

    • 7.4. BLUEFISH PHARMACEUTICALS AB

      • 7.4.1. Company overview

      • 7.4.2. Business performance

      • 7.4.3. Key strategic moves and developments

    • 7.5. NEOCORP GMBH

      • 7.5.1. Company overview

      • 7.5.2. Business performance

      • 7.5.3. Key strategic moves and developments

    • 7.6. NEOPHARM

      • 7.6.1. Company overview

      • 7.6.2. Business performance

      • 7.6.3. Key strategic moves and developments

    • 7.7. SANOFI GENZYME

      • 7.7.1. Company overview

      • 7.7.2. Business performance

      • 7.7.3. Key strategic moves and developments

    • 7.8. BOEHRINGER INGELHEIM GMBH

      • 7.8.1. Company overview

      • 7.8.2. Business performance

      • 7.8.3. Key strategic moves and developments

    • 7.9. ANANT PHARMACEUTICALS PVT. LTD.

      • 7.9.1. Company overview

      • 7.9.2. Business performance

      • 7.9.3. Key strategic moves and developments

    • 7.10. FRESENIUS KABI

      • 7.10.1. Company overview

      • 7.10.2. Business performance

      • 7.10.3. Key strategic moves and developments


 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Asia Pacific Hormone Refractory Breast Cancer Market

Start reading.
This Report and over 66,782+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $2,850
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $2,670
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $4,740
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise
    License/PDF

  • $5,830
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers